Clinical Trials Directory

Trials / Completed

CompletedNCT02143973

Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus

An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
167 (actual)
Sponsor
Trevi Therapeutics · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 24 weeks.

Conditions

Interventions

TypeNameDescription
DRUGnalbuphine HCl ERnalbuphine HCl ER

Timeline

Start date
2014-09-01
Primary completion
2016-01-01
Completion
2016-01-01
First posted
2014-05-21
Last updated
2025-05-21
Results posted
2020-09-07

Locations

35 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02143973. Inclusion in this directory is not an endorsement.